CORT240719C29000
- 4.50
- 0.000.00%
Corcept Therapeutics Newsroom
Express News | Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Zacks.com Featured Highlights Include ADMA Biologics, American Superconductor, Biote, Lincoln Educational Services and Corcept Therapeutics
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Corcept Therapeutics (CORT) and Pfizer (PFE)
Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) Recent Stock Performance Tethered To Its Strong Fundamentals?
Truist Financial Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)
High Insider Ownership Growth Companies On US Exchanges In July 2024
Corcept Therapeutics(CORT.US) Officer Sells US$162.45K in Common Stock
Corcept Therapeutics(CORT.US) Officer Sells US$324.9K in Common Stock
Corcept Therapeutics(CORT.US) Officer Sells US$357.39K in Common Stock
Corcept Therapeutics(CORT.US) Director Sells US$72,182 in Common Stock
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 357.39K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Robb Gary Charles intends to sell 11,000 shares of its common stock on Jul 1, with a total market value of approximately $357.39K
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 162.45K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Lyon Joseph Douglas intends to sell 5,000 shares of its common stock on Jul 1, with a total market value of approximately $162.45
Form 144 | Corcept Therapeutics(CORT.US) Officer Proposes to Sell 324.9K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Corcept Therapeutics(CORT.US)$ Officer Guyer William intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $324.9K. G
Piper Sandler Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $35
Corcept Therapeutics (CORT) Receives a Buy From Piper Sandler
Corcept Therapeutics Announces Results From CATALYST Clinical Trial At ADA's 84th Scientific Sessions; Study Shows 24% Prevalence Of Hypercortisolism In Patients With Difficult-To-Control Type 2 Diabetes; Largest Study To Date With 1,055 Patients
Express News | Corcept Therapeutics Inc - Results Demonstrate a Hypercortisolism Prevalence Rate of 24 Percent in This Patient Population
Express News | Corcept Announces Presentation of Results From Prevalence Phase of Catalyst Clinical Trial at American Diabetes Association’s Scientific Sessions
What Makes Corcept Therapeutics (CORT) a Good Investment Bet?
6 Analysts Have This To Say About Corcept Therapeutics